Thursday, July 9, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ERNA”

213 pharma patents match "ERNA" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 213
Index total 30,257
Page 2 / 9

Quick answer

This filtered view shows 213 pharmaceutical patents matching "ERNA" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

213 results for “ERNA” · 30,257 patents in full index Clear search

  1. US 11478428

    Combinations of beta-lactam compounds and probenecid and uses thereof

    Iterum Therapeutics International Limited · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  2. AU 2021230529

    Use of compounds in the treatment of fungal infections

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Sep 29, 2022 · Expires Sep 24, 2042

    granted
  3. US 11447563

    Tumor selective macropinocytosis-dependent rapidly internalizing antibodies

    The Regents of the University of California · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  4. US 11446253

    Ionic liquids for internal delivery

    The Regents of the University of California · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  5. US 11446357

    Method for treating disease using FOXP3+CD4+ T cells

    Kyverna Therapeutics, Inc. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted
  6. US 11420945

    Solid state forms of Pemafibrate

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  7. US 11407820

    Modulating the alternative complement pathway

    The Regents of the University of Colorado · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  8. US 11306104

    Solid state forms of Relugolix

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  9. US 11278493

    Ophthalmic formulations providing durable ocular lubrication

    ETERNATEAR, INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted
  10. US 11253445

    Oxidative hair color remover in tablet or pellet form

    Bright International, LLC · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  11. US 11220488

    Crystalline polymorph of Ponesimod

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  12. US 11208458

    Compositions and methods for internalizing enzymes

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  13. US 11208493

    Internalizing human monoclonal antibodies targeting prostate and other cancer cells

    The Regents of the University of California · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  14. US 11186626

    Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  15. US 11161828

    Class of bisquaternary ammonium compound as well as the preparative method and the use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted
  16. US 11124835

    Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers

    Transgenion—International Institute for Regenerative Translational Medicine GmbH · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  17. US 11078485

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted
  18. US 11053261

    Solid state forms of ixazomib citrate

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted
  19. US 11033631

    Methods of treating CYP2D6 alternative metabolizers

    Nektar Therapeutics · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  20. US 11028160

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  21. US 11028161

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  22. US 11008564

    Processing engineered FMDV P1 polypeptide using an alternative TEV protease

    The Government of the United States of America, as represented by the Secretary of Homeland Security · Granted May 18, 2021 · Expires May 13, 2041

    granted
  23. AU 2019328599

    Compounds and methods for treating fungal infections

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Apr 22, 2021 · Expires Apr 17, 2041

    granted
  24. US 10981896

    Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase

    The Board of Regents of the University of Texas System · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted